natgillin/translations-raw huggingface dataset:
Hvis dette forekommer, når du har taget Olanzapine Teva, skal du fortælle det til lægen. 
If this happens after you have been given Olanzapine Teva tell your doctor.
Akutte symptomer såsom perspiration, søvnløshed, rysten, angst, kvalme eller opkastning er rapporteret sjældent (≥ 0,01 % og < 0,1 %) når olanzapin stoppes pludseligt. 
Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea, or vomiting have been reported rarely (≥0.01% and <0.1%) when olanzapine is stopped abruptly.
Olanzapine Teva smeltetablet bør placeres i munden, hvor den hurtigt vil dispergeres i spyttet, så den let kan synkes. 
Olanzapine Teva orodispersible tablet should be placed in the mouth, where it will rapidly disperse in saliva, so it can be easily swallowed.
Indeholder blandt andet: lactose, saccharose og aspartam (E951). 
Contains among others: lactose, sucrose and aspartame (E951).
Olanzapin administreret sammen med lithium eller valproat resulterede i øgede værdier (≥ 10 %) af rysten, mundtørhed, øget appetit og øget vægt. 
Olanzapine administered with lithium or valproate resulted in increased levels (≥10%) of tremor, dry mouth, increased appetite, and weight gain.
Der var flere rygere blandt forsøgspersoner med cirrose (4/6; 67 %) end blandt forsøgspersoner uden nedsat leverfunktion (0/3; 
There were more smokers among subjects with cirrhosis (4/6; 67%) than among subjects with no hepatic dysfunction (0/3; 0%).
Dette lægemiddel indeholder 2,25 mg/4,5 mg/6,75 mg/9 mg aspartam i hver 5 mg/10 mg/15 mg/20 mg smeltetablet. 
This medicine contains 2.25 mg/4.5 mg/6.75 mg/9 mg aspartame in each 5 mg/10 mg/15 mg/20 mg orodispersible tablet.
En undersøgelse af den totale omsætning af olanzapin viste imidlertid, at omkring 57 % radioaktivt mærket olanzapin genfandtes i urinen, hovedsageligt som metabolitter. 
A mass balance study showed that approximately 57% of radiolabelled olanzapine appeared in urine, principally as metabolites.
Fortæl altid lægen eller apotekspersonalet, hvis du tager anden medicin eller har gjort det for nylig. 
Tell your doctor or pharmacist if you are taking, have recently taken or might take use any other medicines.
Hyppighederne er defineret som følgende: Meget almindelig (≥ 1/10), almindelig (≥ 1/100 til < 1/10). 
The frequency terms listed are defined as follows: Very common (≥1/10), common (≥1/100 to <1/10).
(≥ 5,17 mmol/l) blev observeret almindeligt. 
(≥5.17 mmol/l) were observed commonly.
Følgende symptomer kan forekomme hos nyfødte af mødre, som har taget Olanzapine Teva i sidste trimester (de sidste tre måneder af graviditeten): rystelser, muskelstivhed og/eller svaghed, søvnighed, ophidselse, vejrtrækningsbesvær og besvær med at indtage føde. 
The following symptoms may occur in newborn babies, of mothers that have used Olanzapine Teva in the last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding.
Hyppighederne er defineret som følgende: Meget almindelig (≥ 1/10), almindelig (≥ 1/100 til < 1/10), ikke almindelig (≥ 1/1.000 til < 1/100), sjælden (≥ 1/10.000 til < 1/1.000), meget sjælden (< 1/10.000), ikke kendt (kan ikke estimeres ud fra forhåndenværende data). 
The frequency terms listed are defined as follows: Very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the data available).
• Carbamazepin (mod epilepsi og stemningsforstyrrelser), fluvoxamin (mod depression) eller ciprofloxacin (mod infektion), da det kan blive nødvendigt at ændre din Olanzapine Teva-dosis. 
- carbamazepine (an anti-epileptic and mood stabiliser), fluvoxamine (an antidepressant) or ciprofloxacin (an antibiotic) - it may be necessary to change your Olanzapine Teva dose.
Meget almindelige symptomer på overdosering (forekomst > 10 %) inkluderer takykardi, agitation/aggressivitet, dysartri, forskellige ekstrapyramidale symptomer og nedsat bevidsthedsniveau, varierende fra sedation til koma. 
Very common symptoms in overdose (>10% incidence) include tachycardia, agitation/aggressiveness, dysarthria, various extrapyramidal symptoms, and reduced level of consciousness ranging from sedation to coma.
DRESS fremtræder indledningsvist som influenzalignende symptomer med udslæt i ansigtet og sidenhen med mere udbredt udslæt, høj temperatur, forstørrede lymfeknuder, forhøjede tal for leverenzymer i blodprøver og et øget antal eosinofile granulocytter (en type hvide blodlegemer). 
DRESS appears initially as flu like symptoms with a rash on the face and then with an extended rash, high temperature, enlarged lymph nodes, increased levels of liver enzymes seen in blood tests and an increase in a type of white blood cell (eosinophilia).
• Olanzapine Teva anbefales ikke til ældre, demente patienter, da det kan have alvorlige bivirkninger. 
- The use of Olanzapine Teva in elderly patients with dementia is not recommended as it may have serious side effects.
Olanzapine Teva indeholder det aktive stof olanzapin. 
Olanzapine Teva contains the active substance olanzapine.
Desuden afslørede et Single Photon Emission Computed Tomography (SPECT) studie af skizofrene patienter, at olanzapinresponderende patienter havde en lavere striatal D2-binding end visse andre antipsykotikaog risperidonresponderende patienter, hvorimod det var sammenligneligt med clozapinresponderende patienter. 
In addition, a Single Photon Emission Computed Tomography (SPECT) imaging study in schizophrenic patients revealed that olanzapine-responsive patients had lower striatal D2 occupancy than some other antipsychoticand risperidone-responsive patients, while being comparable to clozapine-responsive patients.
Olanzapins plasmaproteinbinding var ca. 93 % over koncentrationsintervallet fra ca. 7 til ca. 1.000 ng/ml. 
The plasma protein binding of olanzapine was about 93% over the concentration range of about 7 to about 1000 ng/ml.
Der er risiko for døsighed, når du får Olanzapine Teva. 
There is a risk of feeling drowsy when you are given Olanzapine Teva.
I placebokontrollerede kliniske forsøg (af 6-12 ugers varighed) med ældre patienter (gennemsnitlig alder 78 år) med demensrelateret psykose og/eller adfærdsforstyrrelse var der en dobbelt så høj forekomst af dødsfald hos de olanzapinbehandlede patienter i forhold til de placebobehandlede patienter (henholdsvis 3,5 % og 1,5 %). 
In placebocontrolled clinical trials (6-12 weeks duration) of elderly patients (mean age 78 years) with dementiarelated psychosis and/or disturbed behaviours, there was a 2-fold increase in the incidence of death in olanzapine treated patients compared to patients treated with placebo (3.5% vs. 1.5%, respectively).
Lægemiddelfremka ldt reaktion med eosinofili og systemiske symptomer (DRESS) 
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
• Højt sukker- og fedtindhold (triglycerider og kolesterol) i blodet er set hos patienter, som tager Olanzapine Teva. 
- High blood sugar and high levels of fat (triglycerides and cholesterol) have been seen in patients taking Olanzapine Teva.
Det er vigtigt, at du fortsætter med at tage Olanzapine Teva, så længe din læge beder dig om det. 
It is important that you carry on taking Olanzapine Teva for as long as your doctor tells you.
Patienter med vægtøgning på ≥ 7 %, ≥ 15 % og ≥ 25 % af baseline kropsvægt ved langvarig eksponering (mindst 48 uger) var meget almindelig (henholdsvis 64,4 %, 31,7 % og 
Patients gaining ≥7%, ≥15% and ≥25% of their baseline body weight with long-term exposure (at least 48 weeks) were very common (64.4%, 31.7% and 12.3% respectively).
Farmakoterapeutisk klassifikation: Psykoleptika, diazepiner, oxazepiner , thiazepiner og oxepiner. 
Pharmacotherapeutic group: psycholeptics, diazepines, oxazepines, thiazepines and oxepines.
Patienter, som har taget mere Olanzapine Teva end de burde, har oplevet følgende symptomer: Hurtig hjerterytme, ophidselse/aggression, problemer med at tale, usædvanlige bevægelser (især af ansigt eller tunge) eller nedsat bevidsthedsniveau (døsighed). 
If you take more Olanzapine Teva than you should Patients who have taken more Olanzapine Teva than they should have experienced the following symptoms: rapid beating of the heart, agitation/aggressiveness, problems with speech, unusual movements (especially of the face or tongue) and reduced level of consciousness.
Brug af Olanzapine Teva sammen med alkohol 
Olanzapine Teva with alcohol
Ved langvarig eksponering (mindst 24 uger) tog 89,4 % ≥ 7 % på i vægt, 55,3 % tog ≥ 15 % på i vægt, og 29,1 % tog ≥ 25 % af deres baseline kropsvægt på. 
With long-term exposure (at least 24 weeks), 89.4% gained ≥7%, 55.3%gained ≥15% and 29.1% gained ≥25% of their baseline body weight.
Du bør tage Olanzapine Teva tabletter én gang dagligt efter din læges anvisning. 
You should take your Olanzapine Teva tablets once a day following the advice of your doctor.
Langvarig olanzapinbehandling (op til 12 uger) forebyggende mod tilbagefald hos patienter med bipolær sygdom blev forbundet med en stigning på ≥ 7 % af baseline legemsvægt hos 39,9 % af patienterne. 
Long-term olanzapine treatment (up to 12 months) for recurrence prevention in patients with bipolar disorder was associated with an increase of ≥7% from baseline body weight in 39.9% of patients.
Tag ikke på smeltetabletterne med våde hænder, da de i så fald let vil gå i stykker. 
Do not handle the tablets with wet hands as the tablets may break up.
Det kan være skadeligt for patienter med phenylketonuri (PKU, Føllings sygdom), en sjælden genetisk lidelse, hvor phenylalanin ophobes, fordi kroppen ikke kan fjerne det ordentligt. 
It may be harmful for patients with phenylketonuria (PKU), a rare genetic disorder in which phenylalanine builds up because the body cannot remove it properly.
Pludselig uventet hjertedød 
Sudden cardiac death
- Aktivt stof: olanzapin. 
- The active substance is olanzapine.
• hvis du er allergisk over for olanzapin eller et af de øvrige indholdsstoffer i dette lægemiddel (angivet i punkt 6). 
Do not take Olanzapine Teva: - if you are allergic to olanzapine or any of the other ingredients of this medicine (listed in section 6).
Et lille studie af effekten af nedsat leverfunktion hos 6 forsøgspersoner med klinisk signifikant cirrose (Child-Pugh Class A (n = 5) og B (n = 1)) viste en ringe effekt på farmakokinetikken af oralt administreret olanzapin (2,5-7,5 mg enkeltdosis): Forsøgspersoner med mild til moderat nedsat leverfunktion havde en lettere øget systemisk clearance og hurtigere eliminationshalveringstid sammenlignet med forsøgspersoner uden nedsat leverfunktion (n = 3). 
A small study of the effect of impaired liver function in 6 subjects with clinically significant (Childs Pugh Classification A (n = 5) and B (n = 1)) cirrhosis revealed little effect on the pharmacokinetics of orally administered olanzapine (2.5 - 7.5 mg single dose): Subjects with mild to moderate hepatic dysfunction had slightly increased systemic clearance and faster elimination half-time compared to subjects with no hepatic dysfunction (n = 3).
Det er vist, at Olanzapine Teva forebygger tilbagefald af disse symptomer ved bipolar lidelse (maniodepressiv sygdom) hos patienter, hvis maniske episode har reageret på olanzapinbehandling. 
Olanzapine Teva has been shown to prevent recurrence of these symptoms in patients with bipolar disorder whose manic episode has responded to olanzapine treatment.
DATO FOR FØRSTE MARKEDSFØRINGSTILLADELSE/FORNYELSE AF TILLADELSEN 
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 12.
Under behandling med olanzapin sammen med lithium eller valproat forekom en stigning på ≥ 7 % af baseline legemsvægt hos 17,4 % af patienterne ved akut behandling (op til 6 uger). 
During treatment with olanzapine in combination with lithium or divalproex, an increase of ≥7% from baseline body weight occurred in 17.4% of patients during acute treatment (up to 6 weeks).
Patienter med sjældne, arvelige problemer med frutoseintolerance, glucose-galaktose malabsorption eller sucrase-isomaltasemangel bør ikke tage denne medicin. 
Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
Lactosemonohydrat Hydroxypropylcellulose Crospovidon type A Silica, kolloid vandfri Mikrokrystallinsk cellulose 
Lactose monohydrate Hydroxypropylcellulose Crospovidone type A Silica colloidal anhydrous Microcrystalline cellulose Magnesium stearate
Hvis du holder op med at tage Olanzapine Teva 
If you stop taking Olanzapine Teva
Hæmatologisk toksicitet: Der blev observeret påvirkning af de hæmatologiske parametre i hver dyreart, herunder dosisafhængig reduktion af cirkulerende leukocytter hos mus og ikke-specifik reduktion af cirkulerende leukocytter hos rotter. 
Effects on haematology parameters were found in each species, including dose-related reductions in circulating leukocytes in mice and non-specific reductions of circulating leukocytes in rats; however, no evidence of bone marrow cytotoxicity was found.
Dyreadfærdsundersøgelser af olanzapin indikerede 5-HT, dopamin og kolinerg antagonisme i overensstemmelse med receptorbindingsprofilen. 
Animal behavioural studies with olanzapine indicated 5HT, dopamine, and cholinergic antagonism, consistent with the receptor-binding profile.
Olanzapine Teva er ikke beregnet til patienter under 18 år. 
Children and adolescents Olanzapine Teva is not for patients who are under 18 years.
Forhøjede triglyceridniveauer2 
Elevated triglyceride levels2,5
• Vægtøgning er set hos patienter, som tager Olanzapine Teva. 
- Weight gain has been seen in patients taking Olanzapine Teva.
Olanzapine Teva smeltetabletter knækker let, så du bør tage forsigtigt på smeltetabletterne. 
Olanzapine Teva tablets break easily, so you should handle the tablets carefully.
Hvis du pludseligt holder op med at tage Olanzapine Teva, kan der forekomme symptomer som svedtendens, søvnbesvær, rysten, angst, kvalme og opkastning. 
If you suddenly stop taking Olanzapine Teva, symptoms such as sweating, unable to sleep, tremor, anxiety or nausea and vomiting might occur.
Yderligere oplysninger om dette lægemiddel findes på Det Europæiske Lægemiddelagenturs hjemmeside http://www.ema.europa.eu< og på Lægemiddelstyrelsens hjemmeside http://www.laegemiddelstyrelsen.dk>. 
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu<, and on the website of {name of MS Agency (link)}>.
Hos patienter med nedsat nyrefunktion (kreatinin clearance < 10 ml/min) versus raske forsøgspersoner fandtes ingen signifikant forskel i den gennemsnitlige eliminationshalveringstid (37,7 versus 32,4 timer) eller clearance (21,2 versus 25,0 l/time). 
In renally impaired patients (creatinine clearance <10 ml/min) versus healthy subjects, there was no significant difference in mean elimination half-life (37.7 versus 32.4 hr) or clearance (21.2 versus 25.0 l/hr).
Abstinenssymptom er7,12 
Discontinuation symptoms7,12
I en enkeltdosis (10 mg) Positron Emission Tomography (PET) undersøgelse hos raske forsøgspersoner bandt olanzapin til flere 5-HT2A end til dopamin D2 receptorer. 
In a single oral dose (10 mg) Positron Emission Tomography (PET) study in healthy volunteers, olanzapine produced a higher 5HT2A than dopamine D2 receptor occupancy.
Olanzapin udviste større affinitet til serotonin 5-HT2 end til dopamin D2 receptorerne i in vitro undersøgelser og større 5-HT- end D-aktivitet i in vivo modeller. 
Olanzapine demonstrated a greater in vitro affinity for serotonin 5HT2 than dopamine D2 receptors and greater 5HT than D activity in vivo models.
Hepatitis (inklusive hepatocellulær, kolestatisk eller blandet leverskade)11 
Hepatitis (including hepatocellular, cholestatic or mixed liver injury)
Efter kortvarig behandling (gennemsnitlig varighed 47 dage), var vægtøgning ≥ 7 % af baseline kropsvægt meget almindelig (22,2 %), ≥ 15 % var almindelig (4,2 %) og ≥ 25 % var ikke almindelig (0,8 %). 
Following short term treatment (median duration 47 days), weight gain ≥7% of baseline body weight was very common (22.2%), ≥15% was common (4.2%) and ≥25% was uncommon (0.8%).
Patienter med sjældne, arvelige problemer med galaktoseintolerance, Lapp laktasemangel eller glukose-galaktose malabsorption bør ikke tage denne medicin. 
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
- Øvrige indholdstoffer: mannitol, aspartam (E951), magnesiumstearat, crospovidon type B, lactosemonohydrat, hydroxypropylcellulose, citronsmag (smagsstof(fer), maltodextrin, saccharose, arabisk gummi (E414), glyceryltriacetat (E1518) og alfa-tocopherol (E307). 
- The other ingredients are mannitol, aspartame (E951), magnesium stearate, crospovidone type B, lactose monohydrate, hydroxypropylcellulose and lemon flavour [flavouring preparation(s), maltodextrin, sucrose, gum arabic (E414), glyceryl triacetate (E1518) and alphatocopherol (E307)].
15 Ændringer i de totale kolesterolniveauer ved faste fra normale ved baseline (< 4,39 mmol/l) op til 
15 Changes in total fasting cholesterol levels from normal at baseline (<4.39 mmol/l) to high
Olanzapine Teva 2,5 mg/5 mg/7,5 mg/10 mg filmovertrukne tabletter Color mixture white (polydextose, hypromellose, glyceroltriacetat, macrogol 8000, titandioxid E171) Olanzapine Teva 15 mg filmovertrukne tabletter 
Olanzapine Teva 2.5 mg/5 mg/7.5 mg/10 mg film-coated tablets Colour mixture white (polydextrose, hypromellose, glycerol triacetate, macrogol 8000, titanium dioxide E171)
Fordeling Olanzapins plasmaproteinbinding var ca. 93 % over koncentrationsintervallet fra ca. 7 til ca. 
Distribution The plasma protein binding of olanzapine was about 93% over the concentration range of about 7 to about 1000 ng/ml.
Brug af anden medicin sammen med Olanzapine Teva 
Other medicines and Olanzapine Teva
Olanzapine Teva-filmovertrukket tabletter indeholder lactose. 
Olanzapine Teva film-coated tablets contain lactose.
Dystoni (inklusive okulogyration)11 Tardiv dyskinesi11 Amnesi9 
Tardive dyskinesia11 Amnesia9
Ventrikulær takykardi/ventrikelflimren, pludselig død (se pkt. 
Ventricular tachycardia/fibrill ation, sudden death (see section 4.4)11
Brampton Road, Hampden Park Eastbourne, East Sussex, BN22 9AG Storbritannien 
Brampton Road, Hampden Park Eastbourne, East Sussex, BN22 9AG United Kingdom
Dato for første markedsføringstilladelse: 12. december 2007 Dato for seneste fornyelse: 12. december 2012 
Date of latest renewal: 12.
Citronsmag (smagsstof(fer), maltodextrin, saccharose, arabisk gummi (E414), glyceryltriacetat (E1518) og alfa-tocopherol (E307). 
Lemon flavour [flavouring preparation(s), maltodextrin, sucrose, gum arabic (E414), glyceryl triacetate (E1518) and alpha-Tocopherol (E307)]
I prækliniske undersøgelser udviste olanzapin affinitet (Ki; < 100 nM) til serotonin 5-HT2A/2C, 5-HT3, 5-HT6, dopamin D1, D2, D3, D4, D5, kolinerge muskarine receptorer M1-M5, α1-adrenerge og histamin H1 receptorer. 
5HT2A/2C, 5HT3, 5HT6; dopamine D1, D2, D3, D4, D5; cholinergic muscarinic receptors M1 M5; α1 adrenergic; and histamine H1 receptors.
Olanzapine Teva indeholder lactose, saccharose og aspartam 
Olanzapine Teva contains lactose, sucrose and aspartame This medicine contains lactose and sucrose.
Indeholder, blandt andet, lactosemonohydrat. 
LIST OF EXCIPIENTS Contains, among others, Lactose monohydrate.
En tidsmæssig sammenhæng mellem behandling med olanzapin og venøs tromboembolisme er meget sjældent (< 0,01 %) rapporteret. 
Thromboembolism Temporal association of olanzapine treatment and venous thromboembolism has been reported uncommonly (≥0.1% and <1%).
Trombocytopeni11 
Thrombocytopeni a11
• En kombination af feber, hurtigt åndedræt, svedtendens, muskelstivhed og sløvhed eller søvnighed (hyppigheden af denne bivirkning kan ikke bestemmes ud fra tilgængelige data). 
If you notice any of these symptoms seek medical advice immediately; - a combination of fever, faster breathing, sweating, muscle stiffness and drowsiness or sleepiness (the frequency of this side effect cannot be estimated from the available data).
13 Efter kortvarig behandling (gennemsnitlig varighed 22 dage), var øget vægt ≥ 7 % af baseline legemsvægt (kg) meget almindelig (40,6 %), ≥ 15 % af baseline legemsvægt var almindelig (7,1 %) og ≥ 25 % var almindelig (2,5 %). 
13 Following short term treatment (median duration 22 days), weight gain ≥7% of baseline body weight (kg) was very common (40.6%), ≥15% of baseline body weight was common (7.1%) and ≥25% was common (2.5%).
Lette, forbigående antikolinerge virkninger, herunder forstoppelse og mundtørhed 
Gastrointestinal disorders Mild, transient anticholinergic effects including constipation and dry mouth
Forhøjede plasmaprolaktinniv eauer8 
Investigations Elevated plasma prolactin levels8
Tag dine tabletter lige så snart, du kommer i tanke om det. Du må ikke tage to doser på en dag. 
Do not take two doses in one day.
5 Observeret for fastende normalt niveau ved baseline (< 1,69 mmol/l), der blev øget til højt niveau 
5 Observed for fasting normal levels at baseline (<1.69 mmol/l) which increased to high
Høje niveauer af urinsyre10 
High uric acid10
Du kan komme til at føle dig døsig, hvis Olanzapine Teva tages sammen med depressionsmidler eller medicin til behandling af angst eller søvnløshed (sovepiller). 
Only take other medicines while you are on Olanzapine Teva if your doctor tells you that you can. You might feel drowsy if Olanzapine Teva is taken in combination with antidepressants or medicines taken for anxiety or to help you sleep (tranquillisers).
Color mixture blue (polydextose, hypromellose, glyceroltriacetat, macrogol 8000, titandioxid E171, indigocarmin E132) 
Colour mixture blue (polydextrose, hypromellose, glycerol triacetate, macrogol 8000, titanium dioxide E171, indigo carmine E132)
Hos raske ældre (≥ 65 år) versus ikke-ældre forsøgspersoner var den gennemsnitlige eliminationshalveringstid forlænget (51,8 versus 33,8 timer) og clearance var reduceret (17,5 versus 18,2 l/time). 
In healthy elderly (65 and over) versus non-elderly subjects, the mean elimination half-life was prolonged (51.8 versus 33.8 hr) and the clearance was reduced (17.5 versus 18.2 l/hr).
Hos kvinder versus mænd var den gennemsnitlige halveringstid en del forlænget (36,7 versus 32,3 timer) og clearance reduceret (18,9 versus 27,3 l/timer). 
In female versus male subjects the mean elimination half-life was somewhat prolonged (36.7 versus 32.3 hr) and the clearance was reduced (18.9 versus 27.3 l/hr).
Ændringer i de totale kolesterolniveauer ved faste fra grænser ved baseline (≥ 4,39 - < 5,17 mmol/l) op til (≥ 5,17 mmol/l) var meget almindeligt. 
Changes in total fasting cholesterol levels from borderline at baseline (≥4.39-<5.17 mmol/l) to high (≥5.17 mmol/l) were very common.
Hos olanzapinbehandlede patienter i placebo-kontrollerede kliniske undersøgelser, er der set uønskede forandringer i lipidniveauer (se pkt. 
Undesirable alterations in lipids have been observed in olanzapine-treated patients in placebo-controlled clinical trials (see section 4.8).
Olanzapine Teva indeholder lactose 
Olanzapine Teva contains lactose
Andre medicinsk signifikante sequelae efter overdosering inkluderer delirium, kramper, koma, muligt malignt neuroleptikasyndrom, respirationsbesvær, aspiration, hypertension eller hypotension, hjertearytmi (< 2 % af overdoseringstilfældene) og kardiopulmonært ophør. 
Other medically significant sequelae of overdose include delirium, convulsion, coma, possible neuroleptic malignant syndrome, respiratory depression, aspiration, hypertension or hypotension,
Color mixture pink (polydextose, hypromellose, glyceroltriacetat, macrogol 8000, titandioxid E171, rød jernoxid E172) 
Colour mixture pink (polydextrose, hypromellose, glycerol triacetate, macrogol 8000, titanium dioxide E171, iron oxide red E172)
De anvendes til behandling af følgende lidelser: 
- The other ingredients are: